Sonoma Pharmaceuticals Inc
For the period ended Sep 30, 2024. Filed Nov 7, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2024 · Filed Nov 7, 2024
SNOA$1.13+1.8%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Balance Sheets
(In thousands, except share amounts)
| September 30, 2024 | March 31, 2024 | |
|---|---|---|
| (Unaudited) | ||
| ASSETS | ||
| Current assets: | ||
| Cash and cash equivalents | $4,078 | $3,128 |
| Accounts receivable, net | 3,157 | 2,898 |
| Inventories, net | 2,837 | 2,719 |
| Prepaid expenses and other current assets | 1,929 | 3,541 |
| Current portion of deferred consideration, net of discount | 220 | 262 |
| Total current assets | 12,221 | 12,548 |
| Property and equipment, net | 255 | 365 |
| Operating lease, right of use assets | 162 | 286 |
| Deferred tax asset | 792 | 1,145 |
| Deferred consideration, net of discount, less current portion | 179 | 330 |
| Other assets | 76 | 66 |
| Total assets | $13,685 | $14,740 |
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||
| Current liabilities: | ||
| Accounts payable | $770 | $607 |
| Accrued expenses and other current liabilities | 2,022 | 2,113 |
| Deferred revenue, current portion | 319 | 478 |
| Short-term debt | 82 | 323 |
| Operating lease liabilities, current portion | 116 | 198 |
| Total current liabilities | 3,309 | 3,719 |
| Deferred revenue, net of current portion | 45 | 87 |
| Withholding tax payable | 4,933 | 4,710 |
| Operating lease liabilities, less current portion | 46 | 87 |
| Total liabilities | 8,333 | 8,603 |
| Commitments and Contingencies (Note 5) | – | – |
| Stockholders’ Equity: | ||
| Convertible preferred stock, $0.0001 par value; 714,286 shares authorized at September 30, 2024 and March 31, 2024, respectively, no shares issued and outstanding at September 30, 2024 and March 31, 2024, respectively | – | – |
| Common stock, $0.0001 par value; 50,000,000 and 24,000,000 shares authorized at September 30, 2024 and March 31, 2024, respectively, 1,338,615 and 780,371 shares issued and outstanding at September 30, 2024 and March 31, 2024, respectively (Note 1) (Note 7) | – | – |
| Additional paid-in capital | 205,651 | 203,209 |
| Accumulated deficit | (196,102) | (194,349) |
| Accumulated other comprehensive loss | (4,197) | (2,723) |
| Total stockholders’ equity | 5,352 | 6,137 |
| Total liabilities and stockholders’ equity | $13,685 | $14,740 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.